Resisting antimicrobial resistance (original) (raw)

Nature Reviews Microbiology volume 18, pages 259–260 (2020) Cite this article

Subjects

To control antimicrobial resistance (AMR) will require approaches to develop, share and preserve antibiotics that are scaled to the scientific, economic and ethical dimensions of the crisis. The three cooperative, interdisciplinary, international councils proposed here exemplify what this will require.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Roope, L. S. J. et al. The challenge of antimicrobial resistance: what economics can contribute. Science 364, eaau4679 (2019).
    Article CAS Google Scholar
  2. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016).
  3. Nathan, C. & Cars, O. Antibiotic resistance — problems, progress, and prospects. N. Engl. J. Med. 371, 1761–1763 (2014).
    Article Google Scholar
  4. Laxminarayan, R., Sridhar, D., Blaser, M., Wang, M. & Woolhouse, M. Achieving global targets for antimicrobial resistance. Science 353, 874–875 (2016).
    Article CAS Google Scholar
  5. Nathan, C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304–308 (2007).
    Article CAS Google Scholar
  6. Nielsen, T. B., Brass, E. P., Gilbert, D. N., Bartlett, J. G. & Spellberg, B. Sustainable discovery and development of antibiotics - is a nonprofit approach the future? N. Engl. J. Med. 381, 503–505 (2019).
    Article Google Scholar
  7. Outterson, K. et al. Delinking investment in antibiotic research and development from sales revenues: the challenges of transforming a promising idea into reality. PLoS Med. 13, e1002043 (2016).
    Article Google Scholar
  8. Årdal, C. et al. Drive-AB Report. Revitalizing the antibiotic pipeline. http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf (2018).
  9. Barbier, E. Sustainability: tax ‘societal ills’ to save the planet. Nature 483, 30 (2012).
    Article CAS Google Scholar
  10. Nathan, C. F. Cooperative development of antimicrobials: looking back to look ahead. Nat. Rev. Microbiol. 13, 651–657 (2015).
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Weill Cornell Medicine, New York, USA
    Carl Nathan

Corresponding author

Correspondence toCarl Nathan.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X): https://carb-x.org

Global Antibiotic Research and Development Partnership (GARDP): https://www.gardp.org

Rights and permissions

About this article

Cite this article

Nathan, C. Resisting antimicrobial resistance.Nat Rev Microbiol 18, 259–260 (2020). https://doi.org/10.1038/s41579-020-0348-5

Download citation

This article is cited by